The preliminary findings of a phase two trial show that the coronavirus vaccine being developed by the University of Oxford and AstraZeneca is safe and triggers a similar immune response among all adults.
The promising early-stage results were published in The Lancet, one of the world’s top medical journals, on Thursday.
The study of 560 healthy adults, including 240 over the age of 70-years-old, found the vaccine to be safe and produced a similar immune response among people aged over 56-years-old and those aged between 18 and 55.
British pharmaceutical giant AstraZeneca, which is working in collaboration with the University of Oxford, has previously said interim data showed their experimental vaccine had produced an immune response in older and younger adults.
A safe and effective vaccine is seen by many as a game-changer in the battle against the coronavirus pandemic, which has claimed the lives of over 1.3 million people worldwide.
The Oxford vaccine candidate was found to cause few side effects and triggered immune responses in both parts of the immune system in all age groups and at low and standard doses.